Advances in the study of serum tumor markers of lung cancer

Qi, Wenjie; Li, Xuechang; Kang, Jae-Heon

doi:10.4103/0973-1482.145801

Cited by 20 publications

(6 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Very interestingly, the unexpected oncologic markers CYFRA21-1 and NSE values elevated slightly, which gave us the hint that tumor could not be excluded. Serum tumor markers are considered as biological indicators detected from the serum or plasma of suspected tumor patients with insufficient sensitivity or specificity [ 6 ], which possess the advantages of easy detection, noninvasive operation, and cost-effectiveness [ 6 , 7 ]. For years, the oncologic literature suggests that serum CYFRA21-1 and NSE can be a potential serologic biomarker in evaluation of lung cancer, especially small cell lung cancer (SCLC) [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Recurrent Syncope Associated with Lung Cancer

Zhang

Wang

Yang

2015

Case Reports in Medicine

View full text Add to dashboard Cite

Syncope is an important problem in clinical practice with many possible causes that might be misdiagnosed. We present an unusual case of syncope, which has a normal chest X-ray. Exercise EKG and coronary angioplasty results confirmed the existence of serious coronary heart disease. The patient was treated with coronary stent transplantation. However, scope occurred again and the elevated tumor makers cytokeratin-19-fragment and neuron-specific enolase revealed the bronchogenic carcinoma, which was confirmed by enhanced CT examination. The treatment of carcinoma by chemotherapy was indeed sufficient for prompt elimination of the syncope symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Recurrent Syncope Associated with Lung Cancer

Zhang

Wang

Yang

2015

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…Numerous clinical trials have been conducted to look for markers for advanced-stage NSCLC. Some markers, including CEA, CA19-9, CA125, AFP, NSE, CK20, CDX2, STAT3, CA15-3, and CYFRA21-1, were investigated, but none were found to be specific to cancer [45,46]. MSCs have recently received a lot of attention for their role in the development of various diseases and cancers.…”

Section: Discussionmentioning

confidence: 99%

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

Yang

Gilbertsen

Jacobson

et al. 2023

IJMS

View full text Add to dashboard Cite

Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.

show abstract

“…The role of NSE as a tumor marker is widely accepted in small cell lung cancer (SCLC). However, its prognostic value is controversial in NSCLC (27). Numerous studies explored the prognostic role of NSE in local advanced and metastatic NSCLC and found it as a vital prognostic factor for PFS.…”

Section: Discussionmentioning

confidence: 99%

Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China

et al. 2020

View full text Add to dashboard Cite

This study aims to analyze the prognostic value of seven tumor makers and also investigate the response of palliative chemotherapy in advanced NSCLC patients with advanced disease. Methods: Medical records of 278 advanced NSCLC Chinese patients who received six cycles of palliative chemotherapy were retrospectively reviewed under ethical approval (JSCH2019K-011). Univariate and multivariate Cox regression analyses were performed using SPSS 24 to find the clinical value of these tumor markers and to identify the factors that were associated with progression-free survival (PFS), as well as the response to palliative chemotherapy. Results: In baseline characteristic, the high levels of CEA, CA-125, CA-199, AFP, NSE, CYFRA21-1, and CA15-3 were detected in 209 (75.18%), 139 (50.0%), 62 (22.30%), 18 (6.47%), 155 (55.75%), 176 (63.30%), and 180 (64.74%) patients, respectively. Univariate analysis revealed that patients with high vs. normal levels of all tumor markers had an increased risk of poor prognosis. In the multivariable Cox regression model, the patient with (high vs. normal) CYFRA21-1 levels (HR = 1.454, P = 0.009) demonstrated an increased poor PFS. However, patients with (high vs. normal) CA19-9 levels (HR = 0.524, P < 0.0001) and NSE levels (HR = 0.584, P < 0.0001) presented a decreased risk of PFS. Also, patients receiving 3-drugs regimen had better PFS compared to those on 2-drugs regimen (P = 0.043). Conclusions: The high levels of CYFRA21-1 was correlated with a poor prognostic factor of PFS for Advanced NSCLC patients. However, the high levels of CA19-9 and NSE were associated with a better prognostic factor of PFS. Additionally, smoking habits and tumor status had a poor prognostic factor of PFS. Moreover, we found that antiangiogenic therapy has high efficacy with first-line chemotherapy and longer PFS of NSCLC patients.

show abstract

Advances in the study of serum tumor markers of lung cancer

Cited by 20 publications

References 68 publications

Recurrent Syncope Associated with Lung Cancer

Recurrent Syncope Associated with Lung Cancer

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

Clinical Evaluation of Serum Tumor Markers in Patients With Advanced-Stage Non-Small Cell Lung Cancer Treated With Palliative Chemotherapy in China

Contact Info

Product

Resources

About